Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Role of Osteopontin in Corneal Surface Barrier Function in Type-2 Diabetic Mice
Author Affiliations & Notes
  • ANANYA DATTA
    Biomedical Science and Diseases, New England College of Optometry, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   ANANYA DATTA None
  • Footnotes
    Support  N/A
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 3618. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      ANANYA DATTA; Role of Osteopontin in Corneal Surface Barrier Function in Type-2 Diabetic Mice. Invest. Ophthalmol. Vis. Sci. 2024;65(7):3618.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Osteopontin (OPN) is a proinflammatory glycoprotein shown to be elevated in both human and mouse retinas in the early stages of diabetic retinopathy. Our study was designed to examine the role of OPN in the development of ocular surface complications in Type-2 Diabetic (T2D) mice.

Methods : C57BL/6 wild-type (WT) and OPN-knockout (OPN-/-) mice, aged 3-4 weeks, were fed a high-fat-diet (HFD) for 3 weeks, followed by streptozotocin (STZ) injections for 5 consecutive days to induce T2D. Diabetes (blood glucose > 200 mg/dL) was confirmed 1-2 weeks post-STZ treatment. Post-diagnosis, mice were maintained on HFD with regular STZ injections and blood glucose monitoring. ELISA assays were performed targeting epithelial junctional proteins and fluorescein and wheat germ agglutinin (WGA) staining were used to highlight corneal surface irregularities. These assays were conducted at 4, 6, 8, and 16-weeks post-diabetes onset, with results being compared among diabetic WT and OPN-/- mice, and non-diabetic control mice. One-Way ANOVA was used for statistical analysis with P < 0.05 considered significant.

Results : WT and OPN-/- mice developed T2D within 2 and 3 weeks, respectively, of HFD+STZ treatment. Corneas of WT diabetic mice had significantly higher OPN levels at 4 weeks compared to non-diabetic controls (427.3 ± 5.8 vs. 187.6 ± 1.2 pg/mL; P < 0.0001) and remained significantly elevated at 16 weeks (634.0 ± 20.1 vs. 211 ± 12.3 pg/mL; P < 0.0001). Enhanced fluorescein and WGA staining of corneal irregularities appeared in WT mice at 8 weeks and in OPN-/- mice at 10 weeks post-T2D induction. ELISA analysis over 4-8 weeks of hyperglycemia showed no significant change in ZO-1, ZO-2, Claudin-1, Claudin-4, Claudin-10, and E-Cadherin expression in corneal tissue, irrespective of OPN status. However, at 16 weeks T2D, WT mice exhibited ~1.5, ~1.7, ~1.4, and 1.2-fold significant (P < 0.001) reductions in ZO-1, Claudin-1, Claudin-4, and E-Cadherin respectively, compared to non-diabetic controls and this trend was absent in OPN-/- mice.

Conclusions : Elevated OPN levels in WT corneas were noted at 4 weeks post T2D, without initial subclinical changes. While significant corneal epithelial cell irregularities appeared at 8 weeks, a pattern delayed in OPN-/- mice. Our findings underscore OPN’s involvement in diabetic eye surface complications, pointing to the potential of OPN-targeted therapies in both managing and preventing such issues.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×